Literature DB >> 12670472

Targeting the proteome/epitome, implementation of subtractive immunization.

Andries Zijlstra1, Jacqueline E Testa, James P Quigley.   

Abstract

Monoclonal antibody technology has generated invaluable tools for both the analytical and clinical sciences. However, standard immunization approaches frequently fail to provide monoclonal antibodies with the desired specificity. Subtractive immunization provides a powerful alternative to standard immunization and allows for the production of truly unique antibodies. With the intent of targeting specific epitopes within the proteome, subtractive immunization has been broadly and successfully implemented for the production of monoclonal antibodies otherwise unobtainable by standard immunization. Subtractive immunization utilizes a distinct immune tolerization approach that can substantially enhance the generation of monoclonal antibodies to desired antigens. The approach is based on tolerizing the host animal to immunodominant or otherwise undesired antigen(s) (tolerogen) that may be structurally or functionally related to the antigen of interest. Tolerization of the host animal can be achieved through one of three methods: High Zone, Neonatal, or Drug-induced tolerization. The tolerized animal is then inoculated with the desired antigen (immunogen) and antibodies generated by the subsequent immune response are screened for the desired antigenic reactivity. Over the past 15 years a large number of investigators have used the subtractive approach with cleverly chosen tolerogen-immunogen combinations and successfully generated uniquely reactive antibodies which are often neutralizing or function-blocking. This review will focus on the implementation of subtractive immunization for the production of antibodies otherwise unobtainable by standard immunization.

Mesh:

Substances:

Year:  2003        PMID: 12670472     DOI: 10.1016/s0006-291x(03)00357-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.

Authors:  Paul Anderson; James Louie; Anna Lau; Michael Broder
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

2.  The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.

Authors:  Andries Zijlstra; John Lewis; Bernard Degryse; Heidi Stuhlmann; James P Quigley
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

3.  The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17.

Authors:  Ravindra A De Silva; Dananjaya K Appulage; Halina Pietraszkiewicz; Kevin R Bobbitt; Joe Media; JiaJiu Shaw; Fred A Valeriote; Peter R Andreana
Journal:  Cancer Immunol Immunother       Date:  2012-04       Impact factor: 6.968

4.  Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination.

Authors:  Elena I Deryugina; Erin M Conn; Andreas Wortmann; Juneth J Partridge; Tatyana A Kupriyanova; Veronica C Ardi; John D Hooper; James P Quigley
Journal:  Mol Cancer Res       Date:  2009-08-11       Impact factor: 5.852

Review 5.  Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Histochem Cell Biol       Date:  2008-11-13       Impact factor: 4.304

Review 6.  Enhanced immunization techniques to obtain highly specific monoclonal antibodies.

Authors:  Rodrigo de Almeida; Cecília Naomi Nakamura; Marina de Lima Fontes; Elenice Deffune; Sérgio Luis Felisbino; Ramon Kaneno; Wagner José Fávaro; Athanase Billis; Marcel Otavio Cerri; Ana Marisa Fusco-Almeida; Maria José Mendes Giannini; Andrei Moroz
Journal:  MAbs       Date:  2017-10-06       Impact factor: 5.857

7.  Multiple Tolerization Subtractive Immunization (MTSI) Protocol: Effects on Mice and Monoclonal Antibody Specificity.

Authors:  Marina de Lima Fontes; Franciny Mara de Lima Neves; Kelvin Sousa Santos; Ana Marisa Fusco-Almeida; Maria José Soares Mendes Giannini; Sergio Luis Felisbino; Elenice Deffune; Andrei Moroz
Journal:  Front Immunol       Date:  2021-12-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.